How we treat a hemophilia A patient with a factor VIII inhibitor
- 1 January 2009
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 113 (1), 11-17
- https://doi.org/10.1182/blood-2008-06-160432
Abstract
The most significant complication of treatment in patients with hemophilia A is the development of alloantibodies that inhibit factor VIII activity. In the presence of inhibitory antibodies, replacement of the missing clotting factor by infusion of factor VIII becomes less effective. Once replacement therapy is ineffective, acute management of bleeding requires agents that bypass factor VIII activity. Long-term management consists of eradicating the inhibitor through immune tolerance. Despite success in the treatment of acute bleeding and inhibitor eradication, there remains an inability to predict or prevent inhibitor formation. Ideally, prediction and ultimately prevention will come with an improved understanding of how patient-specific and treatment-related factors work together to influence anti–factor VIII antibody production.Keywords
This publication has 70 references indexed in Scilit:
- Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitorsHaemophilia, 2007
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaThe New England Journal of Medicine, 2007
- Novel therapies for immune tolerance in haemophilia AHaemophilia, 2006
- Rituximab for adolescents with haemophilia and high titre inhibitorsHaemophilia, 2006
- A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitorsJournal of Thrombosis and Haemostasis, 2006
- Rituximab in the treatment of high responding inhibitors in severe haemophilia AHaemophilia, 2006
- The use of recombinant factor VIIa in the treatment of bleeding disordersBlood, 2004
- The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99Journal of Thrombosis and Haemostasis, 2004
- Immune Tolerance for the Treatment of Factor VIII Inhibitors ‐ Twenty Years' ‘Bonn Protocol’Vox Sanguinis, 1996
- Induction of Immune Tolerance in Patients with Hemophilia and Antibodies to Factor VIII by Combined Treatment with Intravenous IgG, Cyclophosphamide, and Factor VIIIThe New England Journal of Medicine, 1988